You are here: Industry Insights > Market News > FDA Revokes EUA for Autobio Diagnostics' Anti-SARS-CoV-2 Rapid Test

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

FDA Revokes EUA for Autobio Diagnostics' Anti-SARS-CoV-2 Rapid Test

americanpharmaceuticalreviewAugust 13, 2020

Tag: FDA , Autobio Diagnostics , SARS-CoV-2

Favorites

The U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) of the Autobio Diagnostics Co. Ltd.'s Anti-SARS-CoV-2 Rapid Tests for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human plasma from anticoagulated blood (Heparin / EDTA / sodium citrate) or serum 2 due to performance concerns with the accuracy of the test. This test may not be distributed.

Previous:Enlivex Announces First Patient Dosed in Allocetra Trial for COVID-19 with Respiratory Failure

Next:FDA Posts Additional Postmarket Information for Essure

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress

PharmaSourcesJune 14, 2024

Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2024 Hybrid Congress.

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

PharmaSourcesJune 11, 2024

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress

PharmaSourcesJune 05, 2024

FDA Revokes EUA for Autobio Diagnostics' Anti-SARS-CoV-2 Rapid Test | Pharmasources.com

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs

PharmaSourcesJune 05, 2024

New research showes that biotechs can save more than 30% in costs, halve start-up times, and cut risk with CROs that have in-house scientific and regulatory affairs.

FDA Revokes EUA for Autobio Diagnostics' Anti-SARS-CoV-2 Rapid Test

Related News

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs

You may like